Literature DB >> 20356849

Medication-induced hypophosphatemia: a review.

G Liamis1, H J Milionis, M Elisaf.   

Abstract

Hypophosphatemia (serum phosphorus concentration <2.5 mg/dl, 0.8 mmol/l), although rare in the general population, is commonly observed in hospitalized patients and may be associated with drug therapy. In fact, hypophosphatemia frequently develops in the course of treatment with drugs used in every-day clinical practice including diuretics and bisphosphonates. Proper diagnostic approach of patients with low serum phosphorus concentrations should involve a detailed medical history with special attention to the recent use of medications. The clinical manifestations of drug-induced hypophosphatemia are usually mild but might also be severe and potentially life-threatening. This review aims at a thorough understanding of the underlying pathophysiological mechanisms and risk factors of drug therapy-related hypophosphatemia thus allowing prevention and effective intervention strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356849     DOI: 10.1093/qjmed/hcq039

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  40 in total

Review 1.  Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia.

Authors:  David B Bregman; Lawrence T Goodnough
Journal:  Ther Adv Hematol       Date:  2014-04

2.  Hypophosphatemia in Critically Ill Children: Risk Factors, Outcome and Mechanism.

Authors:  Satish Kumar Shah; Mohammad Irshad; Nandita Gupta; Sushil Kumar Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2016-07-09       Impact factor: 1.967

Review 3.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

4.  [Osteomalacia-Clinical aspects, diagnostics and treatment].

Authors:  M Tiefenbach; M Scheel; A Maier; M Gehlen; M Schwarz-Eywill; M Werner; U Siebers-Renelt; M Hammer
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

5.  Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.

Authors:  Tariq Chukir; Yi Liu; Katherine Hoffman; John P Bilezikian; Azeez Farooki
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 6.  Bone resorption: supporting immunometabolism.

Authors:  Gustav van Niekerk; Megan Mitchell; Anna-Mart Engelbrecht
Journal:  Biol Lett       Date:  2018-02       Impact factor: 3.703

7.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

8.  Impact of Early Versus Late Diuretic Exposure on Metabolic Bone Disease and Growth in Premature Neonates.

Authors:  Lucas E Orth; Keliana L O'Mara
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

9.  Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.

Authors:  Bernard Regidor; Regina Swift; Benjamin Eades; Marsiye Emamy-Sadr; Fadi Tarhini; Tanya M Spektor; James R Berenson
Journal:  Ann Hematol       Date:  2020-11-25       Impact factor: 3.673

Review 10.  Phosphate imbalance in patients with heart failure.

Authors:  E C Christopoulou; T D Filippatos; E Megapanou; M S Elisaf; G Liamis
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.